HTATIP2

Across TCGA pan-cancer cohorts, HTATIP2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HTATIP2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HTATIP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated HTATIP2 expression acts as an unfavorable survival marker.

CCRCC, GBM, and LUAD are the cancer types where HTATIP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.731	0.943	.001	58	view →
GBM	DFS	Quartile	All	0.284	0.559	.001	17	view →
LUAD	OS	Median	All	0.667	0.858	.013	7	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HTATIP2–CCRCC (OS)

Open the CCRCC breakdown →